Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | CFD | P00746 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30378124 | 1.00 | EGFR (0.43) | EGFRCFDSMN1; SMN2TSHRP2RY12 | |
| SCHEMBL20334288 | 0.90 | CFD (0.42) | CFDSMN1; SMN2TSHRP2RY12IDO1 | |
| SCHEMBL20293753 | 0.88 | EGFR (0.46) | EGFRCFDSMN1; SMN2TSHRP2RY12 | |
| SCHEMBL23308875 | 0.86 | EGFR (0.37) | EGFRSMN1; SMN2TSHRP2RY12IDO1 | |
| SCHEMBL17023825 | 0.82 | CFD (0.56) | CFD | |
| SCHEMBL19208156 | 0.81 | LMNA (0.46) | CFDSMN1; SMN2TSHRRXFP1 | |
| SCHEMBL20334476 | 0.79 | CFD (0.41) | CFDSMN1; SMN2TSHRP2RY12KMT2A | |
| SCHEMBL18556192 | 0.78 | CFD (0.44) | CFDSMN1; SMN2TSHRP2RY12KMT2A | |
| SCHEMBL18554715 | 0.78 | TSHR (0.32) | CFDSMN1; SMN2TSHRIDO1 | |
| SCHEMBL19208544 | 0.75 | LMNA (0.39) | CFDSMN1; SMN2TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210122733-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-04-29 | — | — | US | disclosed |
| US-10906887-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180179185-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122733-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | EGFR 856/4885CFD 1/4885SMN1; SMN2 4623/4885 |
| US-20180179185-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | EGFR 856/4885CFD 1/4885SMN1; SMN2 4623/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | EGFR 856/4885CFD 1/4885SMN1; SMN2 4623/4885 |
| US-10906887-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | EGFR 856/4885CFD 1/4885SMN1; SMN2 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.